Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Ramanathan

Showing results (171-180 of 302) with videos related to

Pageof 31
Sort By:
Oncology|April 15, 2010
A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomasShelly S Lo, Alok A Khorana, Milind Javle, et al.
Investigational New Drugs|August 25, 2011
A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapyRamesh K Ramanathan, Joe J Stephenson, Glen J Weiss, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2005
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancerH Oettle, D Richards, R K Ramanathan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2009
Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignanciesWilliam C Zamboni, Suresh Ramalingam, David M Friedland, et al.
ESMO Open|August 30, 2017
Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohortHoward A Burris, Suzanne Bakewell, Johanna C Bendell, et al.
Annals of Surgical Oncology|November 25, 2010
Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancerPhilip Q Bao, Ramesh K Ramanathan, Alyssa Krasinkas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2015
Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337)Gregory N Dietsch, Tressa D Randall, Raphael Gottardo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trialPatrick J Loehrer, Yang Feng, Higinia Cardenes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2014
A phase I dose-finding study of the novel Toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphomaDonald W Northfelt, Ramesh K Ramanathan, Peter A Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2010
Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumorsRamesh K Ramanathan, Merrill J Egorin, Charles Erlichman, et al.
Pageof 31

Showing results (171-180 of 302) with videos related to

Sort By:
Pageof 31
Oncology|April 15, 2010
A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomasShelly S Lo, Alok A Khorana, Milind Javle, et al.
Investigational New Drugs|August 25, 2011
A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapyRamesh K Ramanathan, Joe J Stephenson, Glen J Weiss, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2005
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancerH Oettle, D Richards, R K Ramanathan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2009
Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignanciesWilliam C Zamboni, Suresh Ramalingam, David M Friedland, et al.
ESMO Open|August 30, 2017
Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohortHoward A Burris, Suzanne Bakewell, Johanna C Bendell, et al.
Annals of Surgical Oncology|November 25, 2010
Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancerPhilip Q Bao, Ramesh K Ramanathan, Alyssa Krasinkas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2015
Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337)Gregory N Dietsch, Tressa D Randall, Raphael Gottardo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trialPatrick J Loehrer, Yang Feng, Higinia Cardenes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2014
A phase I dose-finding study of the novel Toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphomaDonald W Northfelt, Ramesh K Ramanathan, Peter A Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2010
Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumorsRamesh K Ramanathan, Merrill J Egorin, Charles Erlichman, et al.
Pageof 31